Funder: Breakthrough T1D
Due Dates: October 31, 2024 (Letter of Intent) | January 7, 2025 (Full Proposal)
Funding Amounts: Up to $2,000,000 over 3 years for clinical trials; up to $1,000,000 over 3 years for non-interventional studies.
Summary: Supports clinical trials and mechanistic studies testing metabolic therapies (originally for other diseases) to improve outcomes in people with type 1 diabetes.
Key Information: LOI required; funding available to both academic and industry applicants; international applicants eligible.